Antimicrobial Therapy in Intensive Care Unit

This reprint is an excellent collection of articles that deal with difficult-to-treat infections in the ICU environment. Multiresistant bacteria and fungi create severe treatment problems to the physician charged with their care. We hope that this book will help everyday dilemmas and add useful info...

Full description

Saved in:
Bibliographic Details
Other Authors: Paramythiotou, Elizabeth (Editor), Routsi, Christina (Editor), Andremont, Antoine (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:
HAP
VAP
ICU
n/a
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_98906
005 20230405
003 oapen
006 m o d
007 cr|mn|---annan
008 20230405s2023 xx |||||o ||| 0|eng d
020 |a books978-3-0365-6768-6 
020 |a 9783036567693 
020 |a 9783036567686 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-6768-6  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
100 1 |a Paramythiotou, Elizabeth  |4 edt 
700 1 |a Routsi, Christina  |4 edt 
700 1 |a Andremont, Antoine  |4 edt 
700 1 |a Paramythiotou, Elizabeth  |4 oth 
700 1 |a Routsi, Christina  |4 oth 
700 1 |a Andremont, Antoine  |4 oth 
245 1 0 |a Antimicrobial Therapy in Intensive Care Unit 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2023 
300 |a 1 electronic resource (260 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a This reprint is an excellent collection of articles that deal with difficult-to-treat infections in the ICU environment. Multiresistant bacteria and fungi create severe treatment problems to the physician charged with their care. We hope that this book will help everyday dilemmas and add useful information on difficult topics. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a Acinetobacter 
653 |a pandrug-resistant 
653 |a antimicrobial combinations 
653 |a synergy 
653 |a renal replacement therapy 
653 |a Monte Carlo simulation 
653 |a antibiotics 
653 |a pharmacokinetics 
653 |a pharmacodynamics 
653 |a microbiome 
653 |a probiotics 
653 |a intensive care unit 
653 |a dysbiosis 
653 |a ventilator-associated pneumonia 
653 |a extracorporeal membrane oxygenation 
653 |a ECMO 
653 |a critical illness 
653 |a antibiotic choices 
653 |a HAP 
653 |a VAP 
653 |a colonization 
653 |a antibiotic pressure 
653 |a bloodstream infection 
653 |a bacteraemia 
653 |a sepsis 
653 |a septic shock 
653 |a empirical 
653 |a probabilistic antibiotics 
653 |a source control 
653 |a de-escalation 
653 |a ICU 
653 |a intensive care 
653 |a antimicrobial stewardship 
653 |a COVID-19 
653 |a procalcitonin 
653 |a C-reactive protein 
653 |a presepsin 
653 |a infection 
653 |a biomarker 
653 |a guided antimicrobial therapy 
653 |a APACHE II score 
653 |a bacteremia 
653 |a broth microdilution 
653 |a colistin 
653 |a colistin-resistant 
653 |a Gram-negative 
653 |a mortality 
653 |a SOFA score 
653 |a candidemia 
653 |a incidence 
653 |a epidemiology 
653 |a Candida species 
653 |a non-albicans Candida species 
653 |a fluconazole resistance 
653 |a critically ill 
653 |a beta-lactam antibiotics 
653 |a Acinetobacter baumannii 
653 |a antibiotic optimisation 
653 |a antibiotic stewardship (AMS) 
653 |a aspiration pneumonia 
653 |a hospital-acquired pneumonia (HAP) 
653 |a multidrug-resistance (MDR) 
653 |a non-fermentative Gram-negative bacilli (GNB) 
653 |a polymicrobial 
653 |a pneumonia resolution 
653 |a ventilator-associated pneumonia (VAP) 
653 |a carbapenem-resistant A. baumannii (CRAb) 
653 |a infection control 
653 |a antimicrobial agents 
653 |a carbapenems 
653 |a antibiotic resistance 
653 |a clinical pharmacy services 
653 |a Klebsiella pneumoniae 
653 |a Pseudomonas aeruginosa 
653 |a salvage treatment 
653 |a double carbapenem 
653 |a newer β-lactam-β-lactamase inhibitors 
653 |a cefiderocol 
653 |a eravacycline 
653 |a SARS-CoV-2 infection 
653 |a mechanical ventilation 
653 |a risk factors 
653 |a blood stream infection 
653 |a defined daily dose 
653 |a antibiotics utilization 
653 |a empiric 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/6959  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/98906  |7 0  |z DOAB: description of the publication